Cat. No.: HY-N0565

Doxycycline

Name: Doxycycline
Brand: MedChemExpress
SKU: HY-N0565
Price: 36.00 USD
Availability: InStock
Rating: 5 (202 reviews)

202 Cited Publications

Customer Review

Based on 202 publication(s) in Google Scholar

Doxycycline is an orally active, broad-spectrum tetracycline antibiotic that also functions as an MMP inhibitor, exhibiting antibacterial, antiviral, antiparasitic, and antitumor activities. Doxycycline can bind to the classical binding site (CBS) within the mRNA decoding center of the bacterial 70S ribosome's 30S small subunit.Doxycycline blocks bacterial protein synthesis and inhibits the degradation of the extracellular matrix through its interaction with zinc and calcium ions. Doxycycline also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline can disrupt transthyretin (TTR) amyloid fibrils. Doxycycline also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline can be used in research related to cancers—such as breast, prostate, and bladder cancer—as well as neurological disorders.

For research use only. We do not sell to patients.

Purity : 98.20%
CAS No.: 564-25-0
Formula: C₂₂H₂₄N₂O₈
Molecular Weight:444.43

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Doxycycline Chemical Structure

CAS No.: 564-25-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Induced Disease Models
Chemical Information
Publications (202)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]^[10]

Tetracycline

PI3K

Akt

MMP-8

MMP-9

30S subunit

All Antibiotic Isoforms :

All MMP Isoforms :

All Parasite Isoforms :

All Akt Isoforms :

All PI3K Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HeLa	IC₅₀	30 μM Compound: Doxycycline	Compound was evaluated for the inhibition of cell proliferation of human cervix epithelioid carcinoma, HeLa (ATCC CCL2). Compound was evaluated for the inhibition of cell proliferation of human cervix epithelioid carcinoma, HeLa (ATCC CCL2).	10.1016/0960-894X(96)00418-0
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 21741131]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 21852132]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 22889559]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 24946216]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 25282267]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 25791675]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells measured after 72 hrs by MTT assay	[PMID: 27155463]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27654395]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34364164]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37857143]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 38452406]
HepG2	IC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 19482476]
HepG2	IC₅₀	20 μM Compound: doxycycline	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 19926173]
HepG2	IC₅₀	53 μM Compound: Doxycycline	Compound was evaluated for the inhibition of cell proliferation of human hepatocellular carcinoma, HepG2 (ATCC HB8065). Compound was evaluated for the inhibition of cell proliferation of human hepatocellular carcinoma, HepG2 (ATCC HB8065).	10.1016/0960-894X(96)00418-0
HT-1080	IC₅₀	21.4 μM Compound: 7	Inhibition of cell invasion in human HT-1080 cells for 24 hrs by Calcein AM staining based fluorometric analysis Inhibition of cell invasion in human HT-1080 cells for 24 hrs by Calcein AM staining based fluorometric analysis	[PMID: 35969157]
K562	IC₅₀	15 μM Compound: Doxycycline	Cytotoxicity against human K562 cells after 72 hrs by flow cytometry Cytotoxicity against human K562 cells after 72 hrs by flow cytometry	[PMID: 19482476]
K562	IC₅₀	15 μM Compound: doxycycline	Cytotoxicity against human K562 cells after 72 hrs by flow cytometry Cytotoxicity against human K562 cells after 72 hrs by flow cytometry	[PMID: 19926173]
THP-1	IC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide staining-based flow cytometry Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide staining-based flow cytometry	[PMID: 19748781]
THP-1	IC₅₀	3.1 μM Compound: Doxycycline	Selectivity index, ratio of IC50 for human THP1 cells to IC50 for Plasmodium falciparum Selectivity index, ratio of IC50 for human THP1 cells to IC50 for Plasmodium falciparum	[PMID: 19748781]
Vero	IC₅₀	50 μM Compound: Doxycycline	Antiviral activity against DENV2 infected in African green monkey Vero cells assessed as reduction in virus titer after 72 hrs by naphthol blue-black dye based assay Antiviral activity against DENV2 infected in African green monkey Vero cells assessed as reduction in virus titer after 72 hrs by naphthol blue-black dye based assay	[PMID: 31128447]

In Vitro

Doxycycline (11.39 μM + MCF-7; 7.13 μM + MDA-MB-468; 72 h) significantly reduces the population of CD44⁺/CD24^-/low breast cancer stem cells in MCF-7 and MDA-MB-468 cells^[2].
Doxycycline (11.39 μM+MCF-7; 7.13 μM+MDA-MB-468; 72 h) significantly downregulates the mRNA and protein expression of stem cell markers (Nanog, Oct4, Sox2, c-Myc, CD44) in MCF-7 and MDA-MB-468 breast cancer cells^[2].
Doxycycline (1 μg/mL; 5 d) increases the colony formation efficiency of undifferentiated human embryonic stem cells (H9, HSF6, H1, H7, HUES6) and human induced pluripotent stem cells (retrovirus-derived, lentivirus-derived, protein-induced lines), and elevates the number of colonies expressing undifferentiated markers under various culture conditions^[3].
Doxycycline (1 μg/mL; 5 d) promotes the survival and proliferation of H9 human embryonic stem cells (hESC) more effectively than Y-27632 (HY-10071), resulting in larger cell colonies, a higher proportion of undifferentiated AP⁺ cells, as well as downregulated expression of pro-apoptotic genes and upregulated expression of pluripotency-related genes^[3].
Doxycycline (1 μg/mL; 6 d; passage 12) reduces cell apoptosis, increases S-phase cell accumulation, supports the long-term expansion of H9 human embryonic stem cells (H9 hESCs) and Lenti-1 induced pluripotent stem cells (Lenti-1 hiPSCs) cultured in clusters on MEF feeder layers, and maintains the pluripotency and normal karyotype of the cells during repeated passaging^[3].
Doxycycline (1 μg/mL; 7 d) maintains the viability, proliferation and expression of undifferentiated markers of H9 human embryonic stem cells for up to 7 days without medium change, and reduces apoptotic cell death of newly seeded dissociated cells and preformed cell clusters within 3 days without medium change^[5].
Doxycycline (1 μg/mL; 30-72 d) supports long-term subculture of H9, HSF6 human embryonic stem cells as well as Retro-1, Lenti-1, Pro-1 human induced pluripotent stem cells. The culture medium is replaced every 3 days, and the growth rate remains consistent with that under the standard daily medium change condition during passages 5 to 12^[5].
Doxycycline (1 μg/mL; 72 d) maintains normal karyotype, expression of undifferentiated markers and pluripotency (the ability to differentiate into all cells of the three germ layers in vitro) of H9 human embryonic stem cells that are subcultured 12 times with medium replacement every 3 days^[5].
Doxycycline binds to the classical binding site (CBS) within the mRNA decoding center of the bacterial 70S ribosome's 30S small subunit; through magnesium ion coordination, it hinders the binding of tRNA to the A-site^[10].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

LNT-229, G55, and U343 glioma cells
Concentration:

0.01, 0.1, 1 or 10 µg/mL
Incubation Time:

4 days
Result:

Affected growth of glioma cells only under high concentrations (10 µg/mL).

Cell Viability Assay^[2]

Cell Line:

SVG cells
Concentration:

0.01, 0.1, 1 or 10 µg/mL
Incubation Time:

24 hours
Result:

Decreaseed MT-CO1 protein content with concentrations of 1 µg/mL and higher.

Cell Proliferation Assay^[4]

Cell Line:

MCF 12A, 293T cells
Concentration:

100 ng/mL, 1 µg/mL
Incubation Time:

96 hours
Result:

Caused reduced proliferation of MCF 12A and 293T cells at 1 µg/mL.

Cell Viability Assay^[5]

Cell Line:

MCF-7, MDA-MB-468 cells
Concentration:

0-250 μM
Incubation Time:

72 hours
Result:

Inhibited breast cancer cells in a dose-dependent manner with IC₅₀ values for MCF-7 and MDA-MB-468 of 11.39 μM and 7.13 μM respectively.

In Vivo

Doxycycline (25-50 mg/kg; p.o.; twice daily; 10 days) exerts dose-dependent toxic effects on male Wistar rats: a dosage of 50 mg/kg twice daily for 10 consecutive days causes 30% mortality, cardiomyopathy, and significant elevation of biomarkers for muscle and cardiac injury; whereas a dosage of 25 mg/kg twice daily for 10 consecutive days only induces mild skeletal muscle injury without cardiac toxicity^[1].
Doxycycline (60 mg/kg; intraperitoneal injection; once daily for 15 consecutive days) significantly inhibits the growth of CD44v9-expressing prostate cancer xenografts by reducing the proliferation of CD44v9-positive cells^[4].
Supplementary culture of H9 human embryonic stem cells (H9 hESCs) with Doxycycline (1 μg/mL; medium changed every 3 days; up to passage 12) maintains their pluripotency and enables in vivo teratoma formation, which contains all three embryonic germ layers^[5].
Doxycycline (oral gavage; 200 or 800 mg/kg; once daily; 3 months) reduces MMP-9 activity in untreated HT mice in a dose-dependent manner^[3].
Doxycycline (40 mg/kg/day; oral administration; three months) can disrupt transthyretin (TTR) amyloid fibrils and eliminate Congo red-positive amyloid deposits in a transgenic mouse model of familial amyloid polyneuropathy (FAP), without altering the deposition of non-fibrillar TTR. Furthermore, it reduces the levels of fibril-associated markers—such as MMP-9 and serum amyloid P component—in TTR-Met30Val × TTR-KO mice^[9].

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

6-month-old female Heterozygous Col3a1-deficient (HT) mice^[3]
Dosage:

200 or 800 mg/kg
Administration:

Oral gavage; 200 or 800 mg/kg; once daily; 3 months
Result:

Reduced MMP-9 activity in a dose-dependent manner.

Related Protocols :

Induced Disease Models

Doxycycline (Dox) is often used as an inducer in molecular biology studies to induce gene expression. In cells or model animals that have constructed tetracycline induced expression systems (Tet-On/Tet-Off systems), the expression of target genes can be precisely controlled by adding or removing Dox^[7]^[8].
Dose reference for Dox induction^[7]^[8]:
(1) Model animal: male Sprague-Dawley rats
Tet regulatory system: 20-3000 ppm of Dox is supplied in diet.
(2) Model animal: Cags mice
Tet regulatory system: 625 ppm of Dox is supplied in diet.

Induction of Modeling ON-OFF System (Gene expression regulation)^[6]^[7]^[8]

Background

Doxycycline is often used as an inducer in molecular biology research to induce gene expression. In cells or model animals that have constructed a Tetracycline (Tet; HY-A0107) inducible expression (Tet-ON/Tet-OFF) system, the expression of the target gene can be precisely controlled by adding or removing Doxycycline. Doxycycline can act as an inhibitor of transcriptional activation in the Tetracycline (Tc)-controlled transactivation (tTA) system, and as an inducer of transcriptional activation in the "reverse tTA' system. Doxycycline and Tetracycline both act systemically after being absorbed by the upper gastrointestinal tract. In comparison, the main advantage of Doxycycline is that it has a longer activity and can be taken twice or once a day. Although the peak concentrations of the two are similar, Doxycycline takes a shorter time to reach peak concentration and has a significantly longer half-life.

Specific Modeling Methods

Rat^[8]: Sprague-Dawley rats • male • adult middle-aged (12-month-old)
Administration: (for GDNF as targeted gene) 3g/kg (dietary with regular food) • po • once daily for 6 days

Note

(1) Recommend use the recombinant adeno-associated virus (rAAV)-based bicistronic tetracycline (tet)-OFF construct was used for dynamic control of GDNF (target gene) expression during long-term expression^[7].
(2) 3 g/kg dietary DOX produced DOX serum levels equivalent to 1mg/ml DOX in drinking water.

Modeling Indicators

Molecular changes: The expression level of the target gene decreases.

Phenotype changes: The positively correlated phenotype corresponding to the target gene is alleviated.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 564-25-0
Appearance Solid
Molecular Weight 444.43
Formula C₂₂H₂₄N₂O₈
Color Light yellow to brown
SMILES

O=C(N)C(C1=O)=C([C@H]([C@@]2([C@H]([C@@]3([C@H](C4=C(C(O)=CC=C4)C(C3=C([C@@]21O)O)=O)C)[H])O)[H])N(C)C)O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (202)

All WBIn Vivo Efficacy StudyIHCIn Vivo ImagingCell Imaging/StainingRT-PCRELISAIFMicrobiological Assay

Sort by:

Journal Impact Factor

Nature

Ageing promotes metastasis via activation of the integrated stress response. [Abstract]

2026 Apr;652(8112):1339-1348. PMID: 41813904
Cell

2026 Aug 20;189(17):5396-5410.e8. PMID: 42476130
Cell

Sympathetic-epithelial crosstalk governs tissue-resident memory T cell immunosurveillance in the skin. [Abstract]

2026 Mar 5;189(5):1323-1340.e25. PMID: 41616781

Doxycycline purchased from MedChemExpress. Usage Cited in: Cell. 2026 Mar 5;189(5):1323-1340.e25. [Abstract]

Skin CD8⁺ T cells in control and K14-Cxcl16 cKO mice (n = 12–18 skin areas from 2–3 mice per group, two-tailed unpaired t test). To examine whether CXCL16 reduction mediates the decrease in TRM cells following sympathetic activation, CXCL16 levels were reduced by Doxycycline (Dox, 200 mg/kg; i.p.; once daily for 3 consecutive days before euthanasia)-induced Cxcl16 gene knockout in K14rtTA; TetOCre; Cxcl16^fl/fl mice. The results showed a rapid decrease in all skin CD8⁺ TRM cells.
Cell

Extrachromosomal DNA replication and maintenance couple with DNA damage pathway in tumors. [Abstract]

2025 Jun 26;188(13):3405-3421.e27. PMID: 40300601
Cell

Opioid-induced fragile-like regulatory T cells contribute to withdrawal. [Abstract]

2023 Feb 2;186(3):591-606.e23. PMID: 36669483
Mol Cancer

Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells. [Abstract]

2020 Sep 9;19(1):139. PMID: 32907612

Doxycycline purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2020 Sep 9;19(1):139. [Abstract]

ATL cells MT1 stably transfected with a TET-inducible FBXW7 wild type or W425R were induced with doxycycline (2 μg/ml, 24 h) and degradation (WT) or lack thereof (W425R) of endogenous BRAF was confirmed by Western blot.

Doxycycline purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2020 Sep 9;19(1):139. [Abstract]

ATL cells MT1 stably transfected with a TET-inducible FBXW7 wild type, endogenous degradation of BRAF by wild type FBXW7 was confirmed by immunohistochemistry following induction of FBXW7 with doxycycline (2 μg/ml, 24 h).
Mol Cancer

Dying tumor cell-derived exosomal miR-194-5p potentiates survival and repopulation of tumor repopulating cells upon radiotherapy in pancreatic cancer. [Abstract]

2020 Mar 30;19(1):68. PMID: 32228703
Adv Mater

Senescence Reprogramming Unleashes Tumor Immune Surveillance via Coordinated Gene Modulation. [Abstract]

2025 Dec 1:e16597. PMID: 41324273
Cancer Commun (Lond)

2026 Sep 11:46:0048. PMID: 42729649
Cancer Commun (Lond)

Helicobacter pylori CagA elevates FTO to induce gastric cancer progression via a "hit-and-run" paradigm. [Abstract]

2025 May;45(5):608-631. PMID: 39960839

Doxycycline purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 May;45(5):608-631. [Abstract]

Bioluminescence imaging of the lung metastasis burden after inoculation of MKN45 cells with DOX (500 mg/kg, daily, 30 days)-induced CagA expression and MA treatment.

Doxycycline purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 May;45(5):608-631. [Abstract]

After inoculating MKN45 cells with DOX-induced CagA expression and MA treatment, HE staining was performed on lung tissue sections of a specified group. The quantitative results of the number of lung metastases are shown on the right.
Cancer Commun (Lond)

NHE7 upregulation potentiates the uptake of small extracellular vesicles by enhancing maturation of macropinosomes in hepatocellular carcinoma. [Abstract]

2024 Feb;44(2):251-272. PMID: 38152992

Doxycycline purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2024 Feb;44(2):251-272. [Abstract]

The expression of NHE7 in Dox-inducible NHE7-mAID-KO MHCC97L cells with or without doxycycline (DOX, 2 mg/mL) and indole-3-acetic acid (IAA, 50 μg/mL) treatment for 24 h was examined by immunoblotting.

Doxycycline purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2024 Feb;44(2):251-272. [Abstract]

Mice orthotopically injected with NHE7-mAID-KO MHCC97L cells were administered vehicle (DMSO), DOX (2 mg/mL in drinking water containing 5% sucrose), IAA (25 mg/kg/day) and sorafenib (30 mg/kg/day) for 2 weeks (n = 6). Bioluminescence imaging of whole mice was performed at the end of the experiment, and the signal intensity was quantified.

Doxycycline purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2024 Feb;44(2):251-272. [Abstract]

Mice orthotopically injected with NHE7-mAID-KO MHCC97L cells were administered vehicle (DMSO), DOX (2 mg/mL in drinking water containing 5% sucrose), IAA (25 mg/kg/day) and sorafenib (30 mg/kg/day) for 2 weeks (n = 6). Immunohistochemistry of NHE7 and Rab21 in liver tumor tissues.
Nat Genet

Single-nucleus multi-omic profiling of human placental syncytiotrophoblasts identifies cellular trajectories during pregnancy. [Abstract]

2024 Feb;56(2):294-305. PMID: 38267607

Doxycycline purchased from MedChemExpress. Usage Cited in: Nat Genet. 2024 Feb;56(2):294-305. [Abstract]

RT-qPCR analysis of STAT5A and target gene expression in STB-BL with DOX (5 μM, 6 days)-inducible overexpression of STAT5A.

Doxycycline purchased from MedChemExpress. Usage Cited in: Nat Genet. 2024 Feb;56(2):294-305. [Abstract]

RT-qPCR analysis of MITF and target gene expression in STB-BL with DOX (5 μM, 6 days)-inducible overexpression of MITF.

Doxycycline purchased from MedChemExpress. Usage Cited in: Nat Genet. 2024 Feb;56(2):294-305. [Abstract]

ELISA analysis of CSH2 expression in trophoblast organoids derived from hTSCs-BL with DOX (5 μM, 6 days)-inducible overexpression of MITF.

Doxycycline purchased from MedChemExpress. Usage Cited in: Nat Genet. 2024 Feb;56(2):294-305. [Abstract]

Bright fields and immunofluorescence analysis of trophoblast markers (CDH1 and hCG) in trophoblast organoids derived from hTSCs-BL with DOX (5 μM, 6 days)-inducible overexpression of MITF.
Cell Stem Cell

Kidney organoid models reveal cilium-autophagy metabolic axis as a therapeutic target for PKD both in vitro and in vivo. [Abstract]

2024 Jan 4;31(1):52-70.e8. PMID: 38181751
Nat Cell Biol

TOLLIP targets GSDME-NT-carrying endocytic vesicles for autophagy to regulate pyroptosis and chemotherapy efficacy. [Abstract]

2026 Apr;28(4):812-827. PMID: 41803502
Nat Cell Biol

Peritumoural adipose tissue promotes ferroptosis resistance by 3-hydroxykynurenine-mediated suppression of ferritinophagy. [Abstract]

2026 Apr;28(4):783-796. PMID: 41813885
Nat Cell Biol

PRMT5-mediated arginine methylation stabilizes GPX4 to suppress ferroptosis in cancer. [Abstract]

2025 Apr;27(4):641-653. PMID: 40033101

Doxycycline purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2025 Apr;27(4):641-653. [Abstract]

HeLa cells stably expressing tet-on-shScramble (Scr) or tet-on-shMAT2A were pretreated with Doxycycline hydrochloride (Dox, 1 μg/ mL) for two days, and the cell lysates were analysed by immunoblotting with the indicated antibodies.
Cancer Res

Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR-Mutant Non-Small Cell Lung Cancer. [Abstract]

2025 Feb 1;85(3):585-601. PMID: 39514336
Cancer Res

LncRNA AGPG confers endocrine resistance in breast cancer by promoting E2F1 activity. [Abstract]

2023 Oct 2;83(19):3220-3236. PMID: 37463119
Drug Resist Updat

ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer. [Abstract]

2026 Jan:84:101319. PMID: 41192279
Drug Resist Updat

Intercellular adhesion molecule-1 suppresses TMZ chemosensitivity in acquired TMZ-resistant gliomas by increasing assembly of ABCB1 on the membrane. [Abstract]

2024 Sep:76:101112. PMID: 38924997
Nat Microbiol

Characterization of antibiotic resistomes by reprogrammed bacteriophage-enabled functional metagenomics in clinical strains. [Abstract]

2023 Mar;8(3):410-423. PMID: 36759752
Nat Protoc

Inducible CRISPR-Cas9 screening platform to interrogate non-proliferative cellular states. [Abstract]

2025 Oct 8. PMID: 41062702
Protein Cell

Phase separation of DUX family proteins drives totipotent-like state via 3D genome reorganization and retrotransposon activation. [Abstract]

2026 Mar 14:pwag014. PMID: 41832971
Nat Commun

ELMO2 is a therapeutic vulnerability in mesenchymal-like and drug-resistant non-small cell lung cancer. [Abstract]

2026 Apr 17;17(1):5369. PMID: 41997974
Nat Commun

Intraovarian injection of securinine stimulates the growth of small ovarian follicles by reducing stromal suppression. [Abstract]

2026 Apr 13;17(1):5061. PMID: 41974717
Nat Commun

A neurotoxic cryptic peptide arising from TDP-43-dependent cryptic splicing of PKN1. [Abstract]

2026 Feb 20;17(1):2963. PMID: 41720774
Nat Commun

Noncanonical calcium-independent TRPM4 activation governs intestinal fluid homeostasis. [Abstract]

2026 Jan 8;17(1):1253. PMID: 41507162
Nat Commun

Protein kinase A is a dependent factor and therapeutic target in mouse models of fibrous dysplasia. [Abstract]

2025 Jul 1;16(1):5425. PMID: 40593719
Nat Commun

Gadd45g insufficiency drives the pathogenesis of myeloproliferative neoplasms. [Abstract]

2024 Apr 6;15(1):2989. PMID: 38582902
Nat Commun

Reassessing endothelial-to-mesenchymal transition in mouse bone marrow: insights from lineage tracing models. [Abstract]

2023 Dec 20;14(1):8461. PMID: 38123537
Neuron

Social interaction in mice suppresses breast cancer progression via a corticoamygdala neural circuit. [Abstract]

2025 Jul 29:S0896-6273(25)00509-4. PMID: 40752486
Neuron

The paraventricular thalamus mediates visceral pain and anxiety-like behaviors via two distinct pathways. [Abstract]

2025 Jul 23;113(14):2310-2324.e7. PMID: 40345185
Cell Discov

Bacterial toxins induce non-canonical migracytosis to aggravate acute inflammation. [Abstract]

2024 Nov 5;10(1):112. PMID: 39500876
Redox Biol

Targeting PKLR/MYCN/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer. [Abstract]

2023 Jun:62:102686. PMID: 36963289
Mol Cell

Longitudinal monitoring of cytoplasmic RBP-RNA interactions and transcriptome in living cells by engineered protein nanocages. [Abstract]

2026 Jun 25:S1097-2765(26)00378-3. PMID: 42349405
Mol Cell

S-acylation of TDP43 regulates its condensation in amyotrophic lateral sclerosis. [Abstract]

2026 May 12:S1097-2765(26)00270-4. PMID: 42127907
Mol Cell

Targeted citrullination enables p53 binding to non-canonical sites. [Abstract]

2025 Oct 2;85(19):3588-3604.e11. PMID: 41043392
Mol Cell

Lactylation of XLF promotes non-homologous end-joining repair and chemoresistance in cancer. [Abstract]

2025 Jul 17;85(14):2654-2672.e7. PMID: 40680721
Mol Cell

MLKL activity requires a splicing-regulated, druggable intramolecular interaction. [Abstract]

2025 Apr 3:S1097-2765(25)00259-X. PMID: 40209701
Nucleic Acids Res

Enhancing small-molecule-mediated translational control through multivalent RNA aptamers. [Abstract]

2026 Jun 8;54(11):gkag592. PMID: 42273917
Nucleic Acids Res

ALKBH5 governs human endoderm fate by regulating the DKK1/4-mediated Wnt/β-catenin activation. [Abstract]

2024 Oct 14;52(18):10879-10896. PMID: 39166492
Theranostics

Shh and Olig2 sequentially regulate oligodendrocyte differentiation from hiPSCs for the treatment of ischemic stroke. [Abstract]

2022 Mar 28;12(7):3131-3149. PMID: 35547747
Theranostics

Antibiotic Azithromycin inhibits brown/beige fat functionality and promotes obesity in human and rodents. [Abstract]

2022 Jan 1;12(3):1187-1203. PMID: 35154482
J Clin Invest

2026 Aug 4:e206270. PMID: 42550604
J Exp Clin Cancer Res

PHGDH activation fuels glioblastoma progression and radioresistance via serine synthesis pathway. [Abstract]

2025 Mar 19;44(1):99. PMID: 40102981

Doxycycline purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Mar 19;44(1):99. [Abstract]

Nude mice (nu/nu) were surgically engrafted intracranially with GSCs labeled with luciferase and transduced with a Doxycycline hydrochloride (DOX)-inducible system for shPHGDH expression. Mice harboring either GSC19 (A) or GSC29 (B) were randomly assigned to treatment groups (6 mice per group). Starting from day 7 or day 9 post-engraftment, as per the study design (A, B, left), treatments were administered: control, 3 Gy ionizing radiation (IR) delivered weekly over three sessions, 2 mg/mL DOX in the drinking water or a combination of IR and DOX. The progression of GBM xenografts was monitored through bioluminescence imaging, and representative images are displayed (A, B, right).
J Clin Invest

Targeting mitochondrial dynamics of morphine-responsive dopaminergic neurons ameliorates opiate withdrawal. [Abstract]

2024 Jan 18;134(5):e171995. PMID: 38236644
Adv Sci (Weinh)

Targeting PRKCN, an Essential Driver Orchestrating mTOR-IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma. [Abstract]

2026 Apr;13(21):e18975. PMID: 41655233
Adv Sci (Weinh)

Faecalibaculum rodentium Alleviates Ionizing Radiation-Induced Damage in Mice by Improving Intestinal Integrity and Hematopoiesis via Its Metabolite Butyrate. [Abstract]

2025 Oct 13:e09383. PMID: 41082369
Adv Sci (Weinh)

USP8-Governed MDA5 Homeostasis Promotes Innate Immunity and Autoimmunity. [Abstract]

2025 Sep;12(34):e03865. PMID: 40525588
Adv Sci (Weinh)

HACD2 Promotes Pancreatic Cancer Progression by Enhancing PKM2 Dissociation From PRKN in a Dehydratase-Independent Manner. [Abstract]

2025 Mar;12(10):e2407942. PMID: 39836601
Adv Sci (Weinh)

ASH1L in Hepatoma Cells and Hepatic Stellate Cells Promotes Fibrosis-Associated Hepatocellular Carcinoma by Modulating Tumor-Associated Macrophages. [Abstract]

2024 Dec;11(45):e2404756. PMID: 39377228
Adv Sci (Weinh)

A Temporal PROTAC Cocktail-Mediated Sequential Degradation of AURKA Abrogates Acute Myeloid Leukemia Stem Cells. [Abstract]

2022 Aug;9(22):e2104823. PMID: 35652200
Adv Sci (Weinh)

Dual Inhibition of DKC1 and MEK1/2 Synergistically Restrains the Growth of Colorectal Cancer Cells. [Abstract]

2021 Mar 15;8(10):2004344. PMID: 34026451
Sci Adv

Epstein-Barr virus-driven cardiolipin synthesis sustains metabolic remodeling during B cell transformation. [Abstract]

2025 Jan 31;11(5):eadr8837. PMID: 39879311
Sci Adv

RIPK3 deficiency blocks R-2-hydroxyglutarate-induced necroptosis in IDH-mutated AML cells. [Abstract]

2024 Apr 19;10(16):eadi1782. PMID: 38630819
Sci Adv

Tumor suppressor CEBPA interacts with and inhibits DNMT3A activity. [Abstract]

2022 Jan 28;8(4):eabl5220. PMID: 35080973
Cell Death Differ

RIPK3 sequentially recruits MLKL and RIPK1 to induce PANoptosis and chemokine production. [Abstract]

2026 Apr 4. PMID: 41935203
Cell Death Differ

The PLEKHA1-TACC2 fusion gene drives tumorigenesis via vascular mimicry formation in esophageal squamous-cell carcinoma. [Abstract]

2025 Jul 5. PMID: 40615663
Cell Death Differ

NKAP acts with HDAC3 to prevent R-loop associated genome instability. [Abstract]

2023 Jul;30(7):1811-1828. PMID: 37322264
Cell Death Differ

MEK nuclear localization promotes YAP stability via sequestering β-TrCP in KRAS mutant cancer cells. [Abstract]

2019 Nov;26(11):2400-2415. PMID: 30833665
Water Res

Quantifying community-wide antibiotic usage via urban water fingerprinting: Focus on contrasting resource settings in South Africa. [Abstract]

2023 Jul 15:240:120110. PMID: 37247434
Chem Eng J

2025 Oct 8;524:169421.

Doxycycline purchased from MedChemExpress. Usage Cited in: Chem Eng J. 2025 Oct 8;524:169421.

Therapeutic effect of VRC, Doxycycline hydrochloride (Doxy, 0.05 %, 5 μl, 4 times per day for 5 days) on DXMS- associated severe FK. Dynamic phenotype of corneas with different groups observed by slit lamp on each day after infection (n = 6/group).
J Control Release

Hypoxia-responsive Azocalixarene-doxycycline host-guest complex for synergistic myopia control. [Abstract]

2026 Feb 10:390:114586. PMID: 41475499
Cell Death Dis

Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer. [Abstract]

2025 Mar 12;16(1):170. PMID: 40075071
Cell Death Dis

Acquired temozolomide resistance in MGMTlow gliomas is associated with regulation of homologous recombination repair by ROCK2. [Abstract]

2022 Feb 10;13(2):138. PMID: 35145081
Cell Death Dis

Mitochondrial quality control protects photoreceptors against oxidative stress in the H2O2-induced models of retinal degeneration diseases. [Abstract]

2021 Apr 20;12(5):413. PMID: 33879768
Cell Death Dis

SOX1 promotes differentiation of nasopharyngeal carcinoma cells by activating retinoid metabolic pathway. [Abstract]

2020 May 7;11(5):331. PMID: 32382038
Cell Death Dis

FTO is required for myogenesis by positively regulating mTOR-PGC-1α pathway-mediated mitochondria biogenesis. [Abstract]

2017 Mar 23;8(3):e2702. PMID: 28333151
Cancer Lett

Dysregulation of the ALDH1A3/PML-RARα axis promotes the progression of acute promyelocytic leukemia. [Abstract]

2026 Apr 1:642:218280. PMID: 41580016
Cancer Lett

An integrin beta4-EGFR unit promotes hepatocellular carcinoma lung metastases by enhancing anchorage independence through activation of FAK-AKT pathway. [Abstract]

2016 Jun 28;376(1):188-96. PMID: 26996299

Doxycycline purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2016 Jun 28;376(1):188-96. [Abstract]

Doxycycline inducible shRNA can effectivly knockdown the expression of AKT in HCC cells. Cells are treated with 100ng/mL Doxcycline and cultured for the indicated times.
Cell Commun Signal

Receptor activity-modifying protein 1 regulates mouse skin fibroblast proliferation via the Gαi3-PKA-CREB-YAP axis. [Abstract]

2022 Apr 12;20(1):52. PMID: 35413847
J Neuroinflammation

MMPs and NETs are detrimental in CNS-tuberculosis with MMP Inhibition in CNS-tuberculosis mice improving survival. [Abstract]

2025 Oct 11;22(1):230. PMID: 41076519
Phytomedicine

LW-213, a derivative of wogonin, triggers reticulophagy-mediated cell death in NSCLC via lysosomal damage combined with NPC1 inhibition. [Abstract]

2024 Nov:134:155958. PMID: 39241385
Acta Pharmacol Sin

Chromosome instability functions as a potential therapeutic reference by enhancing chemosensitivity to BCL-XL inhibitors in colorectal carcinoma. [Abstract]

2024 Nov;45(11):2420-2431. PMID: 39187678
J Transl Med

KLF14 directly downregulates the expression of GPX4 to exert antitumor effects by promoting ferroptosis in cervical cancer. [Abstract]

2024 Oct 10;22(1):923. PMID: 39390559
Dev Cell

Mitochondrial CCN1 drives ferroptosis via fatty acid β-oxidation. [Abstract]

2025 Apr 18:S1534-5807(25)00206-0. PMID: 40280135
Oncogene

2026 Sep;45(33):3385-3400. PMID: 42420588
Oncogene

TMSB4Y restrains sphingomyelin synthesis via de novo purine synthesis to exert a tumor suppressor function in male esophageal squamous cell carcinoma. [Abstract]

2024 Dec;43(50):3660-3672. PMID: 39443723
Oncogene

SOX10 deficiency-mediated LAMB3 upregulation determines the invasiveness of MAPKi-resistant melanoma. [Abstract]

2024 Feb;43(6):434-446. PMID: 38102338
Apoptosis

The role of KPNA3 in multiple myeloma: implications for targeting nuclear import. [Abstract]

2026 Mar 11;31(3):98. PMID: 41813919
NPJ Parkinsons Dis

Harmol promotes α-synuclein degradation and improves motor impairment in Parkinson's models via regulating autophagy-lysosome pathway. [Abstract]

2022 Aug 6;8(1):100. PMID: 35933473
Int J Mol Med

Overexpression of IFIT2 inhibits the proliferation of chronic myeloid leukemia cells by regulating the BCR‑ABL/AKT/mTOR pathway. [Abstract]

2020 Apr;45(4):1187-1194. PMID: 32124954
J Genet Genomics

A tunable, rapid, and precise drug control of protein expression by combining transcriptional and post-translational regulation systems. [Abstract]

2020 Nov 20;47(11):705-712. PMID: 33549479
Stem Cell Res Ther

SMYD1 modulates the proliferation of multipotent cardiac progenitor cells derived from human pluripotent stem cells during myocardial differentiation through GSK3β/β-catenin&ERK signaling. [Abstract]

2024 Oct 8;15(1):350. PMID: 39380045
Cell Rep

Autoinhibitory control of MLKL governs pseudokinase domain phosphorylation and oligomerization during necroptosis. [Abstract]

2026 Mar 20;45(4):117130. PMID: 41863805
Cell Rep

circATF6 triggers calcium overload to synergize with EGFR-TKI in non-small cell lung cancer via modulation of proteostasis. [Abstract]

2025 Dec 5;44(12):116659. PMID: 41351835
Cell Rep

A generalized strategy to kill leukemic cells by targeting the regulatory systems governing mitochondrial membrane potential. [Abstract]

2025 Nov 25;44(11):116496. PMID: 41166305

Doxycycline purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Nov 25;44(11):116496. [Abstract]

MOLM-13 cells were treated with Doxycycline hydrochloride (25 µM) or Chloramphenicol (25 µM) for 24 h. Mitochondrial translation and MMP were examined (n=3)
Cell Rep

The Hippo pathway kinase MST1 mediates a feedback loop to maintain NLRP3 inflammasome homeostasis. [Abstract]

2025 Jul 26;44(8):116076. PMID: 40716062
Cell Rep

A genome-wide base-editing screen uncovers a pivotal role of paxillin δ ubiquitination in influenza virus infection. [Abstract]

2025 May 26;44(6):115748. PMID: 40434888
Cell Rep

CRISPR screening identifies PRMT1 as a key pro-ferroptotic gene via a two-layer regulatory mechanism. [Abstract]

2024 Aug 22;43(9):114662. PMID: 39178116
Cell Rep

Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis. [Abstract]

2024 Jul 3;43(7):114431. PMID: 38968071
Cell Rep

DOT1L O-GlcNAcylation promotes its protein stability and MLL-fusion leukemia cell proliferation. [Abstract]

2021 Sep 21;36(12):109739. PMID: 34551297
Cell Rep

miR-24 controls the regenerative competence of hair follicle progenitors by targeting Plk3. [Abstract]

2021 Jun 8;35(10):109225. PMID: 34107258
Cell Prolif

Dissection of Mitochondrial Function via Chemical Perturbation and Single-Cell Profiling. [Abstract]

2026 Apr 27:e70216. PMID: 42044679
Cell Prolif

NELFA and BCL2 induce the 2C-like state in mouse embryonic stem cells in a chemically defined medium. [Abstract]

2024 Feb;57(2):e13534. PMID: 37592709
Emerg Microbes Infect

Deep mutational scanning reveals the antibody escape and infectivity landscape of SARS-CoV-2 Omicron JN.1 and XEC receptor-binding domains. [Abstract]

2026 Dec;15(1):2686472. PMID: 42324717
Fundam Res

2025 Jul 8.
Sci Signal

The kinase PLK1 promotes Hedgehog signaling-dependent resistance to the antiandrogen enzalutamide in metastatic prostate cancer. [Abstract]

2025 Mar 18;18(878):eadi5174. PMID: 40100956
Emerg Microbes Infect

AMXT-1501 targets membrane phospholipids against Gram-positive and -negative multidrug-resistant bacteria. [Abstract]

2024 Dec;13(1):2321981. PMID: 38422452
Virulence

Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 against Acinetobacter baumannii. [Abstract]

2026 Dec 31;17(1):2646808. PMID: 41838520
JCI Insight

Therapeutic targeting of YOD1 disrupts the PAX-FOXO1-N-Myc feedback loop in rhabdomyosarcoma. [Abstract]

2025 Dec 16:e193221. PMID: 41401084
Cell Mol Life Sci

2026 Jul 18. PMID: 42470450
J Bone Miner Res

Injectable Matrix Metalloproteinase-Responsive Nanoparticle Hydrogel Scaffold for Sustained Local Drug Delivery in Fibrous Dysplasia. [Abstract]

2026 May 28:zjag091. PMID: 42207164
Biochem Pharmacol

LncRNA HCG11 regulates selinexor sensitivity in multiple myeloma. [Abstract]

2025 Jul:237:116948. PMID: 40228640
Cell Mol Life Sci

The ADCY1-mediated cAMP signaling pathway mediates functional effects of montelukast treatment in brain organoids. [Abstract]

2025 Jun 5;82(1):224. PMID: 40471331
Cell Mol Life Sci

Single-cell transcriptomics reveals liver developmental trajectory during lineage reprogramming of human induced hepatocyte-like cells. [Abstract]

2025 Apr 6;82(1):139. PMID: 40188417
Cell Mol Life Sci

rTM reprograms macrophages via the HIF-1α/METTL3/PFKM axis to protect mice against sepsis. [Abstract]

2024 Nov 16;81(1):456. PMID: 39549085
Inflammopharmacology

Casticin reduces rosacea-related inflammation by inhibiting mast cell activation via Mas-related G protein-coupled receptor X2. [Abstract]

2025 Apr;33(4):1935-1947. PMID: 39821787
Food Funct

Lactobacillus johnsonii 3-1 and Lactobacillus crispatus 7-4 promote the growth performance and ileum development and participate in lipid metabolism of broilers. [Abstract]

2021 Dec 13;12(24):12535-12549. PMID: 34812468
Transl Res

SynNotch-iNOS CAR-macrophages remodel the tumor immune microenvironment and exhibit antitumor efficacy via a CD4+ T cell-dependent mechanism. [Abstract]

2026 Jun 24:S1931-5244(26)00135-0. PMID: 42341916
EMBO Rep

Tudor-based proteomic strategy pan-specifically enriches and identifies protein arginine methylation. [Abstract]

2025 Oct 20. PMID: 41116072
EMBO Rep

UBE2O-mediated ubiquitylation directs cytoplasmic CTNNA1 to promote cell-to-ECM adhesions. [Abstract]

2025 Sep 22. PMID: 40983751
Oncogenesis

Inhibition of LDHB triggers DNA damage and increases cisplatin sensitivity in pleural mesothelioma. [Abstract]

2025 Aug 11;14(1):28. PMID: 40790017
Acta Physiol

Pax8-rtTA/LC1-Driven Inducible Ketohexokinase Deletion Protects Against High Fructose-Induced Metabolic Syndrome in Mice. [Abstract]

2026 Apr;242(4):e70187. PMID: 41792046
Cancer Biol Ther

Curcumin activates NLRC4, AIM2, and IFI16 inflammasomes and induces pyroptosis by up-regulated ISG3 transcript factor in acute myeloid leukemia cell lines. [Abstract]

2022 Dec 31;23(1):328-335. PMID: 35435150
Int J Mol Sci

A Clozapine-Responsive GPCR-Based Gene Switch for Pharmacological Control of Gene Expression in Mammalian Cells and In Vivo. [Abstract]

2026 Apr 9;27(8):3381. PMID: 42074026
Int Immunopharmacol

Identification of RBM3 as a novel regulator of human fetal hemoglobin expression. [Abstract]

2026 Feb 1:170:116107. PMID: 41455370
Int J Mol Sci

O-GlcNAcylation in Gli1+ Mesenchymal Stem Cells Is Indispensable for Bone Formation and Fracture Healing. [Abstract]

2025 Mar 18;26(6):2712. PMID: 40141354
Int Immunopharmacol

Targeting lipid peroxidation-associated ferroptosis suppresses lung carcinoma progression by regulating cell cycle arrest. [Abstract]

2024 Sep 10:138:112518. PMID: 38917528
Front Cell Infect Microbiol

Doxycycline Induces Apoptosis of Brucella Suis S2 Strain-Infected HMC3 Microglial Cells by Activating Calreticulin-Dependent JNK/p53 Signaling Pathway. [Abstract]

2021 Apr 28:11:640847. PMID: 33996626
Biol Res

Perturbation of mammary epithelial cell apicobasal polarity by RHBDF1-facilitated nuclear translocation of PKCζ. [Abstract]

2024 Nov 24;57(1):90. PMID: 39582014
Molecules

Urolithin A Attenuates Periodontitis in Mice via Dual Anti-Inflammatory and Osteoclastogenesis Inhibition: A Natural Metabolite-Based Therapeutic Strategy. [Abstract]

2025 Jul 7;30(13):2881. PMID: 40649395
Molecules

Antibacterial Activity and Mechanism of Canagliflozin against Methicillin-Resistant Staphylococcus aureus. [Abstract]

2023 Jul 26;28(15):5668. PMID: 37570637
PLoS Pathog

YAP Inhibits HIV-1 transcription and promotes HIV-1 latency by regulating E3 ubiquitin ligase UHRF1 mediated tat degradation. [Abstract]

2026 Jan 30;22(1):e1013906. PMID: 41616025
PLoS Pathog

The non-structural protein of SFTSV activates NLRP1 and CARD8 inflammasome through disrupting the DPP9-mediated ternary complex. [Abstract]

2025 Jul 3;21(7):e1013258. PMID: 40608794
Neoplasia

2026 Oct:80:101354. PMID: 42648032
Microorganisms

2026 Aug 23;14(9):1872. PMID: 42795454
J Cell Mol Med

Pharmacological Targeting of DHHC9-Mediated STRN4 Palmitoylation to Suppress YAP-Driven Cancer Metastasis. [Abstract]

2025 Sep;29(17):e70815. PMID: 40903842
Rheumatology (Oxford)

Autophagy inhibitors block pathogenic NET release in immune-mediated inflammatory disease without impairing host defence. [Abstract]

2025 Aug 13:keaf437. PMID: 40802538
J Cell Mol Med

MitoAMPK inhibits the Warburg effect by MZF1-SIRT6 with glycosis related genes in NSCLC. [Abstract]

2024 Sep;28(17):e70053. PMID: 39224032
Virol Sin

Establishment and characterization of a new cell culture system for hepatitis B virus replication and infection. [Abstract]

2022 Aug;37(4):558-568. PMID: 35568375
iScience

2026 Jul 15;29(8):116690. PMID: 42519028
Mol Oncol

CDK12-inactivation-induced MYC signaling causes dependency on the splicing kinase SRPK1. [Abstract]

2024 Oct;18(10):2510-2523. PMID: 38775167
ACS Infect Dis

Lusutrombopag as a Repurposing Drug in Combination with Aminoglycosides against Vancomycin-Resistant Enterococcus. [Abstract]

2024 Apr 12;10(4):1327-1338. PMID: 38567846
iScience

Hepatitis C virus hypervariable region 1 antibodies interrupt E2-SR-B1 interaction to suppress viral infection. [Abstract]

2023 Mar 16;26(4):106421. PMID: 37034976
Ann Lab Med

In Vitro Activity of the Novel Tetracyclines, Tigecycline, Eravacycline, and Omadacycline, Against Moraxella catarrhalis. [Abstract]

2021 May 1;41(3):293-301. PMID: 33303714
FASEB J

CDK9 inhibition activates innate immune response through viral mimicry. [Abstract]

2024 Apr 30;38(8):e23628. PMID: 38661032
FASEB J

Fine particulate matter inhibits phagocytosis of macrophages by disturbing autophagy. [Abstract]

2020 Dec;34(12):16716-16735. PMID: 33124742
Neurobiol Stress

Electroacupuncture attenuates anxiety caused by chronic mild stress through inhibiting NOX2-derived oxidative stress in ventral hippocampus. [Abstract]

2025 Oct 28:39:100768. PMID: 41280328
J Virol

Generation of HBV cccDNA using single-stranded M13 phage DNA for authentic minichromosome functionality. [Abstract]

2026 May 14:e0003526. PMID: 42132423
Microbiol Spectr

Eravacycline for Mycobacterium abscessus infections: pharmacodynamic advantages of long-acting post-antibiotic effects and weekly dosing regimens. [Abstract]

2026 Mar 30;14(5):e0147325. PMID: 41910138
Microbiol Spectr

Antimicrobial resistance of rapidly growing mycobacteria isolated from companion animals in Taiwan. [Abstract]

2025 Jul;13(7):e0307424. PMID: 40387379
J Virol

UBE3C restricts EV-A71 replication by ubiquitination-dependent degradation of 2C. [Abstract]

2024 Oct 22;98(10):e0133524. PMID: 39212385
J Biol Chem

TRIM28 represses renal cell carcinoma cell proliferation by inhibiting TFE3/KDM6A-regulated autophagy. [Abstract]

2023 May;299(5):104621. PMID: 36935008
J Biol Chem

Lysine demethylase KDM1A promotes cell growth via FKBP8-BCL2 axis in hepatocellular carcinoma. [Abstract]

2022 Sep;298(9):102374. PMID: 35970393
mSphere

Aloe emodin isolated from Cassiae semen upregulates IFITM1 to suppress hepatitis B virus replication via the interferon signaling pathway. [Abstract]

2026 Jun 30;11(6):e0031226. PMID: 42274254
Cancer Res Commun

N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma. [Abstract]

2024 Jul 1;4(7):1815-1833. PMID: 38949950
AMB Express

Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms. [Abstract]

2024 Dec 24;14(1):141. PMID: 39718732

Doxycycline purchased from MedChemExpress. Usage Cited in: AMB Express. 2024 Dec 24;14(1):141. [Abstract]

Combinational antimicrobial effects between PVB and conventional antibiotics against MRSA ATCC 43,300. TET, Tetracycline. DOX, Doxycycline. E, Erythromycin. AZI, Azithromycin. P, Penicillin. CAZ, Ceftazidime. AMP, Ampicillin. CEZ, Cefazolin. CEF, Cefotaxime. OXA, Oxacillin. CRO, Ceftriaxone. AMK, Amikacin. GEN, Gentamycin, KANA, Kanamycin. TOB, Tobramycin. SPC, Spectinomycin.
J Med Virol

Hepatitis B Virus Promotes Angiogenesis in Hepatocellular Carcinoma by Increasing m6A Modification of VEGFA mRNA via IGF2BP3. [Abstract]

2025 May;97(5):e70356. PMID: 40260505
J Med Virol

Epstein-Barr virus-driven metabolic alterations contribute to the viral lytic reactivation and tumor progression in nasopharyngeal carcinoma. [Abstract]

2024 May;96(5):e29634. PMID: 38682578
Water

2025 Jun 6.
J Neurooncol

Targeting VAMP5 suppresses PLK1-driven growth of gliomas with high NDRG4 expression. [Abstract]

2026 Jun 8;178(2):50. PMID: 42257837
Infect Drug Resist

2026 May 8;19.
Infect Drug Resist

In vitro Activity of the Novel Tetracyclines Derivative, Zifanocycline Against Mycobacterium abscessus. [Abstract]

2025 Oct 4:18:5239-5247. PMID: 41069760
Infect Drug Resist

Doxycycline-Induced Apoptosis in Brucella suis S2-Infected HMC3 Cells via Calreticulin Suppression and Activation of the IRE1/Caspase-3 Signaling Pathway. [Abstract]

2025 Apr 23:18:2005-2020. PMID: 40290405
FEBS Lett

C9orf72 ALS-causing mutations lead to mislocalization and aggregation of nucleoporin Nup107 into stress granules. [Abstract]

2025 Sep 1. PMID: 40891053
Acta Histochem

YAP promotes wound healing in diabetic mice by improving endothelial cell function via the regulation of SEMA3B. [Abstract]

2026 Apr 27;128(3):152335. PMID: 42048860
Vet Microbiol

Discovery of the tigecycline resistance gene cluster tmexCD3-toprJ1 in Pasteurella multocida strains isolated from pigs in China. [Abstract]

2024 May:292:110046. PMID: 38471428
Clin Exp Pharmacol Physiol

In vitro susceptibility testing of tetracycline-class antibiotics against slowly growing non-tuberculous mycobacteria. [Abstract]

2023 Jul;50(7):604-609. PMID: 37086075
Biochem Biophys Res Commun

TRABID targets DDB2 for deubiquitination to promote proliferation of hepatocellular carcinoma cells. [Abstract]

2022 Oct 15:625:23-30. PMID: 35944360
Biochem Biophys Res Commun

Identification of mutant p53-specific proteins interaction network using TurboID-based proximity labeling. [Abstract]

2022 Jul 30:615:163-171. PMID: 35665610
Arch Oral Biol

ATF5-mediated mitochondrial UPR inhibited RANKL in Porphyromonas gingivalis LPS-treated osteoblasts. [Abstract]

2026 May:185:106556. PMID: 41759254
Diagn Microbiol Infect Dis

A rapid bacterial labeling method for phenotypic antimicrobial susceptibility testing. [Abstract]

2026 Feb;114(2):117181. PMID: 41205476
STAR Protoc

Protocol to generate induced trophoblast stem cells from embryonic stem cells in mice. [Abstract]

2023 Feb 3;4(1):102092. PMID: 36853659
STAR Protoc

Protocol for inducible piggyBac transposon system for efficient gene overexpression in human pluripotent stem cells. [Abstract]

2022 Apr 13;3(2):101296. PMID: 35496784
STAR Protoc

Rapid generation of murine haploid-induced trophoblast stem cells via a Tet-on system. [Abstract]

2021 Nov 5;2(4):100881. PMID: 34806042
STAR Protoc

Protocol for genome-scale CRISPR screening in engineered lineage reporter hPSCs to study cell fate determination. [Abstract]

2021 May 20;2(2):100548. PMID: 34095862
bioRxiv

2026 Sep 8:2026.09.03.749183. PMID: 42818673
bioRxiv

2026 Jul 22:2026.07.21.736123. PMID: 42539318
Res Sq

2026 May 20.
Res Sq

Pdcd4-Rictor Interaction Suppresses PFKFB3 to inhibit Tumorigenesis. [Abstract]

2026 Apr 22:rs.3.rs-9172690. PMID: 42078886
bioRxiv

2026 Jan 26.
bioRxiv

A HaloTag-4R-Tau Pulse-Chase Sensor Reveals Neddylation Inhibition Promotes Degradation of Tau in iNeurons. [Abstract]

2026 Jan 29:2026.01.28.702105. PMID: 41659571
bioRxiv

2025 Sep 10.
bioRxiv

2025 August 09.
bioRxiv

2025 July 10.
bioRxiv

2025 Jun 19.
bioRxiv

2025 May 14.
bioRxiv

2025 April 15.
bioRxiv

2025 March 25.
bioRxiv

2025 January 15.
Research Square Preprint

2024 Dec 04.
Patent

US20190366064A1.
Patent

US11576860B2.
Patent

US20190365645A1.
bioRxiv

2024 July 05.
Heliyon

Pancreatic cancer cells hijack tumor suppressive microRNA-26a to promote radioresistance and potentiate tumor repopulation. [Abstract]

2024 May 15;10(10):e31346. PMID: 38807872
Res Sq

Epstein-Barr-Virus-Driven Cardiolipin Synthesis Sustains Metabolic Remodeling During B-cell Lymphomagenesis. [Abstract]

2024 Apr 8:rs.3.rs-4013392. PMID: 38659762
bioRxiv

2024 Jan 23.
Research Square Preprint

2024 Jan 23.
Biomed Pharmacother

Anti-photoaging effect and mechanism of flexible liposomes co-loaded with apigenin and doxycycline. [Abstract]

2023 Aug:164:114998. PMID: 37301137
Research Square Preprint

2023 Jul 11.
bioRxiv

Musashi-2 (MSI2) regulation of DNA damage response in lung cancer. [Abstract]

2023 Jun 14:2023.06.13.544756. PMID: 37398283
Research Square Print

2023 Mar 1.
bioRxiv

Regulation of VEGFR2 and AKT signaling by Musashi-2 in lung cancer. [Abstract]

2023 Mar 31:2023.03.29.534783. PMID: 37034813
Research Square Print

2022 May.
Elife

RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy. [Abstract]

2021 Oct 27;10:e65759. PMID: 34702444
Charles University

2020 Jul.
Research Square Preprint

2020 Jun.
Patent

US2019/0365645A1.
University of Zürich

2019 Nov.
bioRxiv

2019 Apr.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (225.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2501 mL

11.2504 mL

22.5007 mL

5 mM

0.4500 mL

2.2501 mL

4.5001 mL

10 mM

0.2250 mL

1.1250 mL

2.2501 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (311 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. El-Neweshy MS, et al. Experimental doxycycline overdose in rats causes cardiomyopathy. Int J Exp Pathol. 2013;94(2):109-114. [Content Brief]

[2]. Zhang L, et al. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle. 2017;16(8):737-745. [Content Brief]

[3]. Chang M Y, Rhee Y H, Yi S H, et al. Doxycycline enhances survival and self-renewal of human pluripotent stem cells[J]. Stem cell reports, 2014, 3(2): 353-364.

[4]. Matsumoto T, et al. Doxycycline induces apoptosis via ER stress selectively to cells with a cancer stem cell-like properties: importance of stem cell plasticity[J]. Oncogenesis, 2017, 6(11): 397.

[5]. Chang MY, et al. Doxycycline supplementation allows for the culture of human ESCs/iPSCs with media changes at 3-day intervals. Stem Cell Res. 2015;15(3):608-613. [Content Brief]

[6]. Manfredsson FP, et al. Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol Ther. 2009 Nov;17(11):1857-67. [Content Brief] [Content Brief]

[7]. Kistner A, et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933-8. [Content Brief]

[8]. Niv Y. Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis. Digestion. 2016;93(2):167-73. [Content Brief]

[9]. Cardoso I. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. The FASEB Journal, 2006, 20: 234-239.

[10]. https://pubmed.ncbi.nlm.nih.gov/42225615/

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2501 mL	11.2504 mL	22.5007 mL	56.2518 mL
	5 mM	0.4500 mL	2.2501 mL	4.5001 mL	11.2504 mL
	10 mM	0.2250 mL	1.1250 mL	2.2501 mL	5.6252 mL
	15 mM	0.1500 mL	0.7500 mL	1.5000 mL	3.7501 mL
	20 mM	0.1125 mL	0.5625 mL	1.1250 mL	2.8126 mL
	25 mM	0.0900 mL	0.4500 mL	0.9000 mL	2.2501 mL
	30 mM	0.0750 mL	0.3750 mL	0.7500 mL	1.8751 mL
	40 mM	0.0563 mL	0.2813 mL	0.5625 mL	1.4063 mL
	50 mM	0.0450 mL	0.2250 mL	0.4500 mL	1.1250 mL
	60 mM	0.0375 mL	0.1875 mL	0.3750 mL	0.9375 mL
	80 mM	0.0281 mL	0.1406 mL	0.2813 mL	0.7031 mL
	100 mM	0.0225 mL	0.1125 mL	0.2250 mL	0.5625 mL

Bioz

Doxycycline

202 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Doxycycline

Publications Citing Use of MedChemExpress (MCE) Doxycycline

All Antibiotic Isoforms

All MMP Isoforms

All Parasite Isoforms

All Akt Isoforms

All PI3K Isoforms